jwip
monopoly
openness
two
side
coin
pharmaceutical
industry
olga
gurgula
lecturer
aston
university
candidate
queen
mary
london
ukrainian
qualified
lawyer
correspondence
email
extensively
relies
patent
system
actively
lobby
strengthening
protection
medical
product
result
effort
may
found
majority
bilateral
multilateral
agreement
including
recent
augmented
private
strategy
pursued
company
however
development
show
emerging
tendency
implementing
different
business
model
mark
beginning
transformation
among
open
innovation
increasingly
followed
research
institution
aiming
facilitating
creation
new
affordable
medicine
well
providing
transparency
order
enhance
safety
efficacy
drug
discus
current
strong
access
traditionally
intellectual
property
seen
granted
state
reward
creatorinventor
facilitate
dissemination
knowledge
otherwise
would
kept
secret
type
right
strongest
one
obtain
possession
control
use
protected
importantly
price
author
john
wiley
son
ltd
wileyonlinelibrarycomjournaljwip
world
intellect
prop
classic
example
unique
role
due
specific
feature
hand
invest
significant
financial
resource
time
process
resulted
invention
effective
safe
marketing
vigilant
within
complex
environment
crucial
need
claimed
stem
nature
successful
requires
substantial
considerably
le
investment
copy
therefore
purpose
prevention
free-riding
rely
main
argument
articulated
high
cost
amount
million
angell
frank
light
warburton
morgan
grootendorst
lexchin
cunningham
greyson
sector
inquiry
billion
grabowski
hansen
according
figure
tested
compound
successfully
launched
para
study
go
far
claiming
made
developed
introduced
commerce
unavailable
mansfield
hence
accepted
oriented
idea
contrast
form
trade
kulakowski
chronister
copyright
design
despite
attractive
advantage
power
provided
great
interest
softwarebased
used
way
instead
restricting
user
eg
linux
sometimes
royalty-free
basis
deriving
income
service
support
tailor-made
software
created
antipode
traditional
so-called
copyleft
proving
monopolistic
best
explained
restrictively
protect
market
also
source
free
information
outline
first
position
aimed
mean
international
instrument
practice
turn
towards
facilitated
organisation
authority
individual
initiative
upon
modern
relatively
young
considered
offspring
dyestuff
chemical
establishment
closely
linked
incidental
discovery
willian
henry
perkin
scientist
royal
college
chemistry
firn
greenwood
pp
myers
given
task
synthesise
quinine
coal-tar
industrial
waste
gas
lighting
dutfield
although
unsuccessful
initial
nevertheless
discovered
dyeing
mauve
eventually
led
several
completely
synthetic
dominated
german
bayer
hoechst
became
famous
dye
later
like
merck
eli
lilly
roche
supplied
natural
morphine
strychnine
started
large-scale
production
taylor
importance
scientific
entirely
available
country
recently
nineteenth
century
europe
typically
producing
patentable
boldrin
levine
meant
manufacture
sell
using
making
invested
considerable
convert
nonpatentable
subject
matter
arguably
compared
level
signing
aspect
grand
victory
big
pharma
heavily
lobbied
finally
set
matthew
minimum
standard
establishes
rule
provides
shall
whether
field
technology
involve
inventive
step
capable
application
emphasis
added
mandatory
extended
treaty
every
signatory
member
undertook
obligation
introduce
national
legislation
implement
relevant
mechanism
registration
enforcement
change
particularly
detrimental
developing
could
afford
burden
administrative
adequate
examination
lacking
necessary
bear
expensive
patented
understanding
challenge
flexibility
parallel
importation
compulsory
licensing
possibility
frame
exhaustion
patentability
requirement
value
curtailed
signed
united
nation
conference
panel
report
tend
strengthen
regional
provision
usually
higher
required
believed
delay
generic
entry
lead
restricted
concern
excessive
pricing
partnership
described
twenty-first
implying
similar
appear
future
voon
substantially
elevates
comparing
correa
instance
extension
year
term
compensation
unreasonable
unnecessary
authorisation
adjustment
office
party
make
involves
thus
mirror
adding
following
section
confirms
least
us
known
method
provide
opportunity
engage
evergreening
allow
extend
beyond
basic
moreover
previous
version
chapter
proposed
leaked
february
contained
additional
sentence
guaranteed
even
enhancement
love
phrase
deleted
subsequent
unprecedented
corporation
withdrawal
discussion
ratification
remaining
continue
favourable
likely
effect
come
force
gained
introducing
law
increased
last
decade
barrier
competitor
enable
increase
tool
arsenal
together
regulatory
exclusivity
scope
dual
strategic
approach
block
competition
stifle
innovative
particular
raised
case
commission
abuse
dominant
originator
accused
concerned
misleading
obtaining
supplementary
certificate
unlawful
losec
omeprazole
second
related
misuse
procedure
employed
deter
entering
original
expire
success
able
keep
fined
general
court
upheld
decision
anticompetitive
evident
failure
in-depth
investigation
released
cause
brand-name
share
employing
tool-box
include
inter
alia
thicket
life-cycle
follow-on
bansal
sahu
bakshi
singh
granstrand
tietze
hemphill
sampat
defensive
patenting
settlement
federal
staff
referring
reason
become
focus
attention
litigated
investigated
lack
detriment
consumer
leading
acknowledged
seminal
ever
greater
necessarily
socially
beneficial
fence
erected
growing
benefit
society
perceived
occurred
thing
decrease
approval
data
science
trend
important
freely
shared
anyone
participate
robertson
et
al
shaw
willis
burrow
hooft
van
huijsduijnen
speed
wide
network
expert
disclosure
positive
negative
reduction
duplication
worldwide
mimic
movement
acknowledging
achievement
ibid
present
mainly
driven
academic
public
number
shown
moving
collaboration
achieving
september
completing
extensive
reviewing
numerous
submission
various
stakeholder
promoting
health
secretary
aim
review
ass
proposal
recommend
solution
remedying
policy
incoherence
justifiable
inventor
human
context
recommended
publicly-funded
widely
completed
discontinued
clinical
trial
publically
vaccine
publicly
accessible
database
eleven
major
funders
non-governmental
council
médecins
sans
frontières
bill
melinda
gate
foundation
wellcome
trust
joint
statement
agreeing
require
fund
registered
disclosed
press
release
unreported
often
progress
leave
incomplete
potentially
picture
risk
device
suboptimal
harmful
alternative
incentive
incentivise
meet
global
delink
end
observatory
monitor
analyse
function
integration
funding
pipeline
publication
etc
venture
participation
established
expertise
community
promote
diagnostics
fight
neglected
tropical
disease
malaria
tuberculosis
granting
know-how
taken
determined
examine
oxfam
briefing
paper
horizon
€bn
programme
adopted
undertaken
mandating
open-access
publishing
encouraging
prize
another
public-private
european
federation
association
sharing
create
better
flagship
missing
discussed
bias
literature
jones
rising
bacchetti
bero
turner
linardatos
tell
rosenthal
regarding
dziura
post
zhao
fu
peduzzi
goldacre
molenberghs
kenward
large
proportion
evidence
much
reported
done
inadequately
unpublished
unfavourable
contain
fact
withheld
undermines
confidence
prescribed
doctor
many
promoted
safer
really
endangers
people
life
tackling
problem
past
full
announced
longer
publish
commit
anonymised
patient
reasonable
request
journal
published
coverage
adverse
outcome
associated
hidden
restoring
invisible
abandoned
randomised
controlled
remained
reanalysis
cast
doubt
survival
surgery
curative
resection
colorectal
cancer
independent
respect
infamous
paroxetine
paxil
seroxat
tolerated
treatment
depression
adolescent
noury
subsequently
dubbed
food
administration
failed
neither
placebo
campaign
showed
prepared
writer
paid
manufacturer
disturbing
emerged
serious
self-harm
suicidal
ideation
department
justice
misconduct
commenced
criminal
civil
proceeding
record
$bn
fine
exacerbated
document
submitted
body
consider
part
dossier
commercial
confidential
releasable
agency
regulator
give
doshi
jefferson
koenig
october
medicinal
came
january
allows
proactively
objective
scrutiny
cover
reactive
third
proactive
summary
register
cameron
knapper
evans
implemented
diverge
spanning
generated
latter
precompetitive
proven
early
stage
help
expand
shorter
period
exception
becoming
rather
isolated
well-known
private-public
rockefeller
three
government
gabriel
stanley
saunders
goal
reduce
disease-endemic
discovering
delivering
antimalarial
belongs
novartis
obliged
distribute
endemic
initiated
pathogen
box
contains
diverse
drug-like
molecule
active
charge
google
parent
alphabet
bioelectronic
miniature
electronic
implant
chronic
asthma
diabetes
arthritis
condition
gradual
shift
launch
anticipated
structural
genomics
consortium
abbvie
boehringer
ingelheim
canada
são
paulo
genome
janssen
ontario
ministry
pfizer
takeda
receives
output
pearson
researcher
receive
patient-level
reviewed
perhaps
element
guard
group
vigorously
fighting
enhanced
pressure
forced
licence
prohibitive
relates
gileads
sovaldi
sofosbuvir
hepatitis
generation
offer
efficiency
boasting
sustained
virologic
response
fewer
option
included
list
essential
mezher
per
pill
-week
quarter
sold
hensley
hoofnagle
sherker
estimated
infected
live
cannot
knox
lancet
triggered
outcry
debate
throughout
advocacy
demanded
gilead
lower
criticised
gileard
entered
india
activist
argue
forfeit
served
funded
suspended
exchanged
hubbard
refers
congress
allocate
budget
pay
cash
remove
say
divorce
starting
gone
began
afforded
culminated
highest
hardly
nowadays
supplemented
abusive
reluctant
act
fearing
affect
innovate
proprietary
achieved
aggressive
prohibitively
unaffordable
believe
forgotten
creating
cure
mega
called
sole
reaping
yield
increasing
apparent
scene
operates
changing
framing
reality
adapt
collaborating
genuinely
willingness
combat
poverty
orphan
others
either
acting
voluntarily
survive
soon
salute
defeat
dominance
clear
sign
ice
cracked
back
conclude
experiencing
today
tension
powerful
strives
revenue
advocate
hard
predict
prevail
constant
hold
degree
accumulation
hopping
foreclose
interested
healthcare
attorney
prior
commencement
worked
counselling
range
corporate
involved
litigation
arbitration
concerning
dispute
see
truth
deceive
u
random
house
ouellette
take
michigan
telecommunication
umichedumttlrvoliss
accessed
heated
estimate
economics
stating
since
demythologizing
systematic
tuft
center
reach
england
formula
nearly
-year-old
management
bartlet
publisher
economic
game
theory
explain
french
forbade
permission
limited
eventual
ban
germany
allowed
prohibition
obtained
switzerland
prohibited
constitution
italy
foreign
spain
joined
always
detail
negotiation
preceding
conclusion
globalising
routledge
pre-grant
opposition
restriction
curtailment
explains
issuance
five
filing
territory
whichever
jargon
protects
secondary
formulation
leak
consolidated
text
pandering
orgnode
complete
node
officially
withdraws
decreased
euro
appeal
rejected
patentrelated
exchange
intervention
andor
reimbursement
critic
concept
lundbeck
perindopril
servier
actavis
inc
slip
op
cephalon
ensures
gain
relinquished
refund
purchaser
affected
cy
news-eventspress-releasesftc-settlement-cephalon-pay-delay-case-ensures--billion-ill
pay-for-delay
pay-offs
includes
indian
norwegian
epicentre
arm
coalition
epidemic
preparedness
institut
pasteur
resolution
sixty-sixth
assembly
reference
page
bad
broken
fix
fourth
estate
arguing
half
never
formerly
british
ben
centre
evidencebased
cochrane
james
lind
sense
dartmouth
geisel
school
institute
petition
weekly
peer-reviewed
oldest
influential
originally
guide
transforming
open-innovation-health-guide-transforming-healthcare-through-collaboration
boilerplate
website
not-for-profit
directive
carry
relevance
core
mandate
determine
structure
scale
cost-effectively
targeting
protein
biomedical
parasite
represent
potential
target
area
respectively
responsible
deposited
bank
implication
therapy
obesity
psychiatric
disorder
issued
principle
sharing-become-effective-today
york
question
hep
news
online
cnsnewscomnewsarticlemedical-groups-question-price-new-hep-c-drug
controversial
issue
milieu
south
series
freedom
biomedcentralcomarticless---
must
faster
guardian
impact
nd
edn
dealing
analysis
yale
biology
releasejoint-efpia-phrma-principles-for-responsible-clinical-trial-data-sharing-become-effective-today
veterinary
november
indexjspcurl=pagesspecialtopicsgeneralgeneralcontentjsp
final
union
communication
social
committee
region
shaped
ftc-settlement-cephalon-pay-delay-case-ensures--billion-ill
proper
balance
govos
working
antimicrobial
chronicle
twentieth
triumph
verily
establish
galvani
bioelectronics
dedicated
costly
shred
sale
shot
blog
nprorgblogshealthcostly-hepatitis-c-pill-shreds-drug-industry-sales-record
c-the
framework
handler
crowell
keil
weaver
non-publication
randomized
cross
sectional
availabe
maker
look
cut
overseas
blogshealthmaker-of---hepatitis-c-pill-looks-to-cut-its-cost-overseas
slattery
grove
lang
benjamini
day
posch
biometrical
burlington
nardo
healy
jureidini
raven
tufanaru
harm
imipramine
adolescence
empirical
edward
elgar
import
perspective
presented
renmin
china
fundamental
lesson
gdansk
high-level
call
papersview
edumttlrvoliss
trading
away
revisited
agenda
continues
undermine
fully
embraced
yet
genengnewscominsight-and-intelligenceopen-innovation-in-the-pharma-industry
march
reporting
presentation
journalsplosorgplosmedicinearticleid=journalpmed
ylioja
williamson
woelfle
robin
badiola
todd
tutorial
parasitology
fair
deal
bulletin
organization
hester
harrison
ed
selective
antidepressant
influence
nrd
en
financing
coordination
consultative
intersection
liberalisation
co-operation
legal
cite